Bayer Agreements was Atara Biotherapeutics’s largest revenue line in fiscal 2022, bringing in $61.80M of $63.60M (97%).
| Collaborative Arrangement and Arrangement Other than Collaborative | FY 2022 |
|---|---|
| Bayer Agreements | $61.80M |
| Ar Commercialization Agreement | $1.80M |
| Total | $63.60M |
Atara Biotherapeutics brought in $63.60M from its two revenue lines in fiscal 2022, the year ended December 31, 2022. Bayer Agreements was the largest at $61.80M (97.2%), ahead of Ar Commercialization Agreement at $1.80M (2.8%).
Atara Biotherapeutics (ATRA) reports its revenue by collaborative arrangement and arrangement other than collaborative. In fiscal 2022, Bayer Agreements was its largest revenue line, bringing in $61.80M (97.2% of the total), followed by Ar Commercialization Agreement at $1.80M (2.8%).
Bayer Agreements was Atara Biotherapeutics' largest revenue line in fiscal 2022, bringing in $61.80M, or 97.2% of the $63.60M total across its two revenue lines.
Every figure comes from Atara Biotherapeutics' annual financial filings, as reported. Each line keeps the name Atara Biotherapeutics gives it, and years follow its fiscal calendar.
Atara Biotherapeutics' revenue by collaborative arrangement and arrangement other than collaborative goes back to fiscal 2022, with figures through fiscal 2022. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.